Elmiron Class Action Lawsuit - Canada

What is this lawsuit about?

Slater Vecchio LLP has filed a proposed lawsuit against Janssen Inc. and Teva Branded Pharmaceutical Products R&D, Inc. on behalf of Canadians who were prescribed and ingested Elmiron. The lawsuit alleges that Elmiron causes an undisclosed serious permanent vision loss side effect known as pigmentary maculopathy.

What is pigmentary maculopathy?

Pigmentary maculopathy is a permanent vision-threatening eye disease characterized by changes to pigment cells in the area of the retina responsible for sharp, detailed central vision.

What symptoms are associated with Elmiron?

Individuals with pigmentary maculopathy may experience one or more of the following symptoms:

• Change in eye colour
• Blurred vision
• Difficulty reading
• Poor light to dark adaptation
• Dark spots in vision
• Straight lines appearing warped or curved
• Loss of vision
• Muted, less vivid colours

Who is affected?

Pigmentary maculopathy is associated with long-term Elmiron use.

Because the drug companies did not warn of the risk of pigmentary maculopathy on the label for Elmiron, many individuals may have not been diagnosed, or may have been diagnosed with other eye conditions.

The signature changes of pigmentary maculopathy are only visible with the technology used to record images of the interior surface of the eye.

What should proposed class members do now?

Doctors are recommending that anyone who has used Elmiron undergo a complete eye exam to see if any damage has been done.

If you are a Canadian who has taken Elmiron, we invite you to connect with us and share your story by submitting the form on this page with your information.  This will contribute to the case being brought against the manufacturers of this drug.